Business
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of
About this update from Rapport Therapeutics, Inc.
[{"type":"text","content":"Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Rapport to receive upfront cash payment of $20 million, up to $308 million in potential development and commercial milestones and other payments, and mid-single-digit to mid-teens tiered royalties BOSTON and SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport”) a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, and Tenacia Biotechnology (Hong Kong) Co., Ltd (“Tenacia”), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, today announced a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including in mainland China, Hong Kong, Macau and Taiwan. RAP-219 is a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being developed as part of Rapport’s growing neuroscience portfolio, including in focal onset seizures (FOS) and primary generalized tonic-clonic seizures, as well as in bipolar mania. In September 2025, Rapport announced the results of a Phase 2a trial of RAP-219 in patients with drug-resistant FOS. In the trial, RAP-219 demonstrated a statistically significant reduction in long episodes, an objective electrographic biomarker for clinical seizure reduction, compared with baseline, and a statistically significant and clinically meaningful reduction in clinical seizures compared with baseline. RAP-219 was generally well tolerated. Two global registrational trials of RAP-219 will be conducted in FOS, with the Phase 3 program expected to be initiated in the second quarter of 2026. Tenacia’s regional expertise will expand the global reach of RAP-219 and will accelerate development efforts for RAP-219 in FOS by adding Phase 3 clinical trial sites in China under Tenacia’s leadership. Under the terms of the agreement, Rapport is eligible to receive an upfront payment of...